| Title |
Neuroprotective Effects of Resveratrol Against Aβ Administration in Rats are Improved by Lipid-Core Nanocapsules
|
|---|---|
| Published in |
Molecular Neurobiology, January 2013
|
| DOI | 10.1007/s12035-013-8401-2 |
| Pubmed ID | |
| Authors |
Rudimar L. Frozza, Andressa Bernardi, Juliana B. Hoppe, André B. Meneghetti, Aline Matté, Ana M. O. Battastini, Adriana R. Pohlmann, Sílvia S. Guterres, Christianne Salbego |
| Abstract |
Alzheimer's disease (AD), a neurodegenerative disorder exhibiting a gradual decline in cognitive function, is characterized by the presence of neuritic plaques composed of neurofibrillary tangles and amyloid-β (Aβ) peptide. Available drugs for AD therapy have small effect sizes and do not alter disease progression. Several studies have been shown that resveratrol is associated with anti-amyloidogenic properties, but therapeutic application of its beneficial effects is limited. Here we compared the neuroprotective effects of free resveratrol treatment with those of resveratrol-loaded lipid-core nanocapsule treatment against intracerebroventricular injection of Aβ1-42 in rats. Animals received a single intracerebroventricular injection of Aβ1-42 (2 nmol), and 1 day after Aβ infusion, they were administered either free resveratrol (RSV) or resveratrol-loaded lipid-core nanocapsules (5 mg/kg, each 12 h, intraperitoneally), for 14 days. Aβ1-42-infused animals showed a significant impairment on learning memory ability, which was paralleled by a significant decrease in hippocampal synaptophysin levels. Furthermore, animals exhibited activated astrocytes and microglial cells, as well as disturbance in c-Jun N-terminal kinase (JNK) and glycogen synthase kinase-3β (GSK-3β) activation, beyond destabilization of β-catenin levels. Our results clearly show that by using lipid-core nanocapsules, resveratrol was able to rescue the deleterious effects of Aβ1-42 while treatment with RSV presented only partial beneficial effects. These findings might be explained by the robust increase of resveratrol concentration in the brain tissue achieved by lipid-core nanocapsules. Our data not only confirm the potential of resveratrol in treating AD but also offer an effective way to improve the efficiency of resveratrol through the use of nanodrug delivery systems. |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 112 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 24 | 21% |
| Student > Ph. D. Student | 20 | 18% |
| Student > Bachelor | 13 | 12% |
| Student > Doctoral Student | 7 | 6% |
| Researcher | 6 | 5% |
| Other | 12 | 11% |
| Unknown | 30 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 19% |
| Biochemistry, Genetics and Molecular Biology | 12 | 11% |
| Agricultural and Biological Sciences | 11 | 10% |
| Medicine and Dentistry | 7 | 6% |
| Neuroscience | 6 | 5% |
| Other | 23 | 21% |
| Unknown | 32 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2013.
All research outputs
#18,337,420
of 22,708,120 outputs
Outputs from Molecular Neurobiology
#2,450
of 3,431 outputs
Outputs of similar age
#219,475
of 282,554 outputs
Outputs of similar age from Molecular Neurobiology
#11
of 16 outputs
Altmetric has tracked 22,708,120 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,431 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,554 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.